市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | NovaBridge Biosciences | - | - |
AIStockmoo 评分
0.9
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.88 |
|
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Hhlr Advisors, Ltd. | 31 Mar 2026 | 5,980,568 |
| Aihc Capital Management Ltd | 31 Mar 2026 | 2,262,933 |
| Exome Asset Management Llc | 31 Mar 2026 | 576,960 |
| Point72 Hong Kong Ltd | 30 Sep 2025 | 561,366 |
| Fiera Capital Corp | 31 Mar 2026 | 315,681 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合